Rapport Therapeutics, Inc.
RAPP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002012593
In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Rapport Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 35 | 55 | +20 |
| Shares | 25.6M | 28.4M | +2.89M (+11.3%) |
| Value | $593.4M | $581.9M | −$11.6M (−1.9%) |
New holders (30)
Institutions that held Rapport Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (10)
Institutions that held Rapport Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 350,000 | $8.14M |
| Millennium Management LLC | 116,782 | $2.72M |
| Saturn V Capital Management LLC | 70,000 | $1.63M |
| Monashee Investment Management LLC | 40,000 | $930.4K |
| Alyeska Investment Group, L.P. | 34,731 | $807.8K |
| Soros Fund Management LLCSuperinvestorSoros Fund Management | 30,000 | $697.8K |
| Squarepoint Ops LLC | 16,345 | $380.2K |
| Two Sigma Investments, LP | 13,000 | $302.4K |
| Balyasny Asset Management LLC | 10,000 | $232.6K |
| Davidson Kempner Capital Management LP | 10,000 | $228.6K |